Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
IGC Pharma, Inc.
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
May 15, 2026
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
April 28, 2026
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
April 22, 2026
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
April 14, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
April 8, 2026
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer’s Disease
April 7, 2026
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
March 30, 2026
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer’s Research
February 26, 2026
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
January 30, 2026
←
Previous Page
1
2
3
Next Page
→